3.6 The effects of Budesonide nebulization combined with
intravenous Vitamin C on the SI-ALI in vitro
We further employed the LOC as a platform to explore the therapeutic
efficacy of budesonide nebulization in conjunction with intravenous
Vitamin C for mitigating SI-ALI. This treatment regimen was based on
clinical medication standards[18]. Following smoke
exposure, 2.4 mg/ml Vitamin C was introduced into the upper chamber for
4 hours, while budesonide (diluted with normal saline at a 1:1 ratio)
was administered into the lower chamber for 30 minutes. The results
showed that the drug combination significantly reduced oxidative stress
(Figure 7A). The mRNA expression of IL-1β, NF-κB, TNF-α, and IL-10
decreased in both epithelial and endothelial cells (Figures 7B-a, c, d,
f). IL-6 expression decreased in the endothelium but showed no
significant change in the epithelium (Figure 7B-b). The gene expression
of caspase-3, a crucial apoptotic molecule, also decreased in both cell
types within the treatment group (Figure 7B-e). These findings provide
experimental evidence supporting the clinical application of budesonide
nebulization combined with intravenous Vitamin C for reducing
inflammation, oxidative stress, and apoptosis in fire-related SI-ALI.